• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
YE Lianbao, WU Jieyu, YANG Jiebo, LUO Jiaoyan, HU Qiaohong. Synthesis of the related substances of gefitinib[J]. Journal of China Pharmaceutical University, 2014, 45(6): 667-670. DOI: 10.11665/j.issn.1000-5048.20140608
Citation: YE Lianbao, WU Jieyu, YANG Jiebo, LUO Jiaoyan, HU Qiaohong. Synthesis of the related substances of gefitinib[J]. Journal of China Pharmaceutical University, 2014, 45(6): 667-670. DOI: 10.11665/j.issn.1000-5048.20140608
shu

Synthesis of the related substances of gefitinib

More Information
    Graphical Abstract
    • Abstract
  • To strengthen the quality control over gefitinib and establish its quality criterion, four related substances of gefitinib were identified based on the synthetic route and synthesized, and their structures were confirmed by 1H NMR and MS. These substances were 4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-ol( A ), N-(3-chloro-4-fluorophenyl)-6, 7-dimethoxyquinazolin-4-amine( B ), 4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)propylamino)ethanol( C )and N-(3, 4-dichlorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine( D ).
    • FullText(HTML)
    • References (8)
  • [1]
    AstraZeneca plc(GB).Oncolytic EGF receptor tyrosine kinase inhibitor IressaTM[J].Drugs Future,2002,27(4):339-345.
    [2]
    Zhang H,Zhao JH,Wang H.Synthesis of 4-(3-chloro-4-fluoro-phenylamineo)-7-methoxy- 6-(3-morpholin-4-yl-propoxy)-quinazoline: CN,200810122242.2[P].2009-04-08.
    [3]
    Lv TJ,Ouyang QP,Meng XB,et al.Synthesis of gefitinib[J].Guangzhou Chem Ind(广州化工),2010,38(12):154-156.
    [4]
    Xi YY,Zhang QW.Synthesis of gefitinib[J].Chin J Pharm(中国医药工业杂志),2008,39(6):401-403.
    [5]
    Xie LH, Ouyang GP. Process Improvement on the synthesis of gefitinib[J].Chin J Synth Chem(合成化学),2010,18(4):523-525.
    [6]
    Xiao HL,Wang P,Wang YJ,et al.Improved synthesis of gefitinib[J].J Ocean Univ China(中国海洋大学学报),2010,40(8):103-106.
    [7]
    Jin B,Chen GH,Zhou AF,et al.Synthesis of gefitinib[J].J China Pharm Univ(中国药科大学学报),2005,36(1):92-94.
    [8]
    Li XS, Zhang AQ, Huang L. Process for the preparation of gefitinib:CN,200910192850.5[P].2009-09-30.
    • Related Articles

  • Related Articles

    [1]QIAN Qianqian, LI Guozhi, TIAN Hong, GAO Xiangdong. Design, preparation, and antitumor activity of fusion protein vaccine based on tumor antigen PBK[J]. Journal of China Pharmaceutical University, 2024, 55(5): 657-665. DOI: 10.11665/j.issn.1000-5048.2024030801
    [2]ZHOU Hongyou, GAO Xiangdong, YAO Wenbing, TIAN Hong. Screening of adjuvant for PD-L1 vaccine based on nitrated T cell epitope[J]. Journal of China Pharmaceutical University, 2024, 55(3): 397-403. DOI: 10.11665/j.issn.1000-5048.2023032801
    [3]LI Mengyuan, JIANG Xiaomeng, SUN Qinyi, GUO Wei. Research progress of CAR-T immunotherapy in solid tumors combined with new strategies[J]. Journal of China Pharmaceutical University, 2023, 54(4): 443-449. DOI: 10.11665/j.issn.1000-5048.2023030101
    [4]SHAO Shishuai, DUAN Shukang, TIAN Hong, YAO Wenbing, GAO Xiangdong. Design and antitumor activity of programmed cell death ligand 1 epitope peptide vaccine[J]. Journal of China Pharmaceutical University, 2023, 54(2): 245-254. DOI: 10.11665/j.issn.1000-5048.2023022803
    [5]WANG Zhenghao, GAO Yafeng, ZHANG Lianjun, LIU Chang. Research progress of T cell anti-tumor function regulated by endoplasmic reticulum stress[J]. Journal of China Pharmaceutical University, 2022, 53(5): 518-524. DOI: 10.11665/j.issn.1000-5048.20220502
    [6]YAO Zheng, LI Zihan, GAO Liming, HU Xing, CHEN Yan, PAN Wenqi, LI Qian. Advances of research on CAR-T cell immunotherapy for solid tumors[J]. Journal of China Pharmaceutical University, 2021, 52(4): 496-504. DOI: 10.11665/j.issn.1000-5048.20210413
    [7]XIA Xuefei, ZHANG Li, LUO Jianhua, YAO Wenbing, GAO Xiangdong, TIAN Hong. Design and antitumor activity of immune checkpoint B7-H3 epitope vaccine[J]. Journal of China Pharmaceutical University, 2021, 52(4): 472-479. DOI: 10.11665/j.issn.1000-5048.20210410
    [8]CHEN Hongmei, KANG Yanliang, LIU Li, YAO Wenbing, TIAN Hong. Effects of different immunogenic amino acids in PD-L1 vaccine on the differentiation of T cell subsets[J]. Journal of China Pharmaceutical University, 2020, 51(3): 349-356. DOI: 10.11665/j.issn.1000-5048.20200313
    [9]JIANG Liangliang, JIANG Tao, LUO Jianhua, YAO Wenbing, TIAN Hong. A novel human immune system mice model for assessing the immunogenicity of cancer vaccines[J]. Journal of China Pharmaceutical University, 2019, 50(6): 734-742. DOI: 10.11665/j.issn.1000-5048.20190615
    [10]SUN Zhan-yi, CAI Hui, HUANG Zhi-hua, SHI Lei, CHEN Yong-xiang, LI Yan-mei. Advances of glycopeptide-associated tumor vaccines[J]. Journal of China Pharmaceutical University, 2012, 43(2): 97-106.

Catalog

    Get Citation
    PDF
    XML
    Article views PDF downloads Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：365820

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return